1. Home
  2. POM vs APRE Comparison

POM vs APRE Comparison

Compare POM & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo POMDOCTOR LIMITED American Depositary Shares

POM

POMDOCTOR LIMITED American Depositary Shares

HOLD

Current Price

$0.97

Market Cap

11.3M

ML Signal

HOLD

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.81

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
POM
APRE
Founded
2015
2006
Country
China
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.3M
11.5M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
POM
APRE
Price
$0.97
$0.81
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.10
AVG Volume (30 Days)
95.9K
44.9K
Earning Date
05-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.06
$0.55
52 Week High
$6.43
$1.69

Technical Indicators

Market Signals
Indicator
POM
APRE
Relative Strength Index (RSI) 51.35 68.82
Support Level $0.17 $0.77
Resistance Level $1.15 $0.81
Average True Range (ATR) 0.13 0.06
MACD 0.01 0.01
Stochastic Oscillator 52.84 80.00

Price Performance

Historical Comparison
POM
APRE

About POM POMDOCTOR LIMITED American Depositary Shares

Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of its revenue is derived from the Pharmaceutical supply chain segment.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: